RSS

Helsinn

Mundipharma and Helsinn Group have extended their licensing and distribution agreement for the anti-emetic agent ALOXI to now include Vietnam. more

News

Swiss pharmaceutical group, Helsinn, and professional pharmaceutical subsidiary of CJ Group, CJ Healthcare, have announced that the oral formulation of AKYNZEO has been approved for use in Korea by the Korean Ministry of Food and Drug Safety (MFDS). more

News

Helsinn — a Swiss pharmaceutical group — and Glenmark Pharmaceuticals — a research-led global pharma company — have launched a fixed combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV), AKYNZEO, to the Indian market more

News

Swiss pharmaceutical group, Helsinn, has revealed it will be investing €6 million at its drug product supply centre (Helsinn Birex Pharmaceuticals — HBP) in Dublin, Ireland, to safeguard its supply chain and compliance with regulatory requirements more

News

Swiss pharmaceutical group, Helsinn, has announced the launch of the intravenous formulation of AKYNZEO (a fixed combination of fosnetupitant, 235 mg, and palonosetron, 0.25 mg) in the US. more

News

Here, we reveal some of the news, developments and product innovations that have been released from the show floor of day 1 of this year’s CPhI Worldwide congress in Frankfurt more

News

Swiss pharmaceutical group, Helsinn, has opened an office in Shanghai, China, as part of the group’s commitment to the region — Helsinn Pharmaceuticals (Beijing). more

News

Swiss-based pharma group Helsinn has revealed its US subsidiary (Helsinn Therapeutics) has signed a co-promotion agreement with Novartis for Zykadia more

News

Helsinn’s anamorelin HCI has been accepted for marketing authorisation application (MAA) review by the European Medicines Agency (EMA) more

News